Granata Bio is a Boston-based biopharmaceutical company building a portfolio of fertility and reproductive-health therapies. Founded in 2018, it in-licenses and develops medications used in IVF outside the US, runs its own clinical programs, and is expanding into ovarian biology. Its lead asset is an investigational human menopausal gonadotropin in the pivotal Phase III GRACE study, and its 2025 acquisition of Oviva Therapeutics added a first-in-class therapeutic aimed at extending ovarian function. The company targets the multi-billion-dollar global infertility medication market with the goal of expanding patient access and improving IVF outcomes.
Samphire Neuroscience is a London-based neurotechnology company building drug-free, hormone-free wearables for women's health. Its flagship product, Nettle, is a headband that uses transcranial direct current stimulation (tDCS) to gently modulate the brain regions tied to mood and pain, worn 20 minutes a day in the run-up to menstruation. Marketed as the first EU-cleared (CE-certified) neuromodulation device for women's health, Nettle targets PMS, PMDD, menstrual pain and related hormonal conditions. Founded in 2021 by neuroscientist Emilė Radytė and IP lawyer Alex Cook, the company has raised roughly $7.77M across pre-seed, seed and Series A rounds.
Emilė Radytė is a Harvard- and Oxford-trained neuroscientist and the co-founder and CEO of Samphire Neuroscience, a London-based neurotech company building drug-free, hormone-free wearable devices for menstrual health. Her flagship product, Nettle, is a head-worn device using non-invasive transcranial direct current stimulation (tDCS) to target the neurological drivers of menstrual pain and mood symptoms. Named to the Forbes 30 Under 30 Healthcare list in 2024, she came up through emergency medicine at Harvard and a PhD in psychiatry and engineering at Oxford, and reframes conditions like PMS and PMDD as questions of brain circuitry rather than hormones alone.
Alloy Health is a direct-to-consumer women's telehealth company built to fix how medicine treats menopause. Founded by Anne Fulenwider and Monica Molenaar, Alloy connects women in perimenopause and menopause with menopause-trained doctors and a full menu of FDA-approved, science-backed treatments - hormone replacement therapy, vaginal estrogen, plus hair, skin, sexual-wellness, gut and weight solutions - delivered to the door via an asynchronous platform with a flat $50 annual membership. The company raised a $16M Series A in November 2024 and reached profitability while serving women historically dismissed by the healthcare system.
Marissa Fayer is a 25-year medtech executive who runs DeepLook Medical, an AI diagnostics company that helps radiologists spot breast cancer earlier in women with dense breast tissue, which she took from concept through FDA clearance into global commercialization. She is also the founder of HERhealthEQ, a nonprofit that has reached over 128,000 women across 12 countries by deploying medical devices for cancers, maternal health, and cardiovascular disease. A partner at women's-health fund Goddess Gaia Ventures and author of the forthcoming book 'Undervalued to Unavoidable,' she argues women's health is not a charitable cause but economic infrastructure that has been systematically underestimated.
Midi Health is a national virtual care clinic built specifically for women in perimenopause, menopause, and the long midlife stretch that mainstream medicine has historically ignored. Founded by Joanna Strober after her own frustrating search for symptom relief, Midi pairs clinicians trained in menopause medicine with an insurance-covered telehealth platform that treats hot flashes, sleep problems, weight changes, mood swings, and long-term hormone health. Now valued above $1 billion after a $100M Series D in February 2026, Midi serves more than 230,000 patients across all 50 states.
Vivoo is a San Francisco-based health tech company that makes at-home urine test strips analyzed via smartphone camera. Founded in 2017, the company offers a wellness platform that measures 8+ biomarkers — including hydration, vitamins, minerals, pH, ketones, and oxidative stress — and delivers personalized nutrition and lifestyle recommendations through a free mobile app. Backed by $19.4M in funding led by Tim Draper, Vivoo is sold at Target, Walmart, and Sam's Club, and has expanded to 100+ countries with a focus on making lab-grade health insights accessible to everyday consumers.
Neda Razavi is the CEO and Chairwoman of the Board at iSono Health, a South San Francisco medtech company building the world's first wearable, automated, portable FDA-cleared 3D breast ultrasound system. With 25 years of experience launching 65 products across six global platforms and generating over $9 billion in cumulative revenue at companies including Abbott, Roche, Medtronic, and Natera, Razavi joined iSono Health as an early investor and advisor before taking the helm in November 2023 to lead commercialization of the ATUSA system — a 2-minute, hands-free breast imaging device that pairs robotics, AI, and cloud analytics to make early breast cancer detection accessible to OB/GYNs and primary care providers without requiring a trained sonographer.
Anarghya Vardhana is a venture partner at Maveron, the consumer-only VC firm co-founded by Howard Schultz, where she has spent nearly a decade backing iconic consumer brands in health, wellness, and social tech. A Stanford grad who published a math theorem at 17, she moved from Sandia National Labs nuclear research to Google international ops to the boardrooms of startups like Co-Star, Bend Health, and Alife. Forbes named her a 30 Under 30 in VC and their First Diversity Champion across the entire class. Simultaneously serving as Investor in Residence at Vanta, she is one of the few investors who credibly bridges deep technical rigor with consumer intuition - and who also runs trail marathons and dances Bharatanatyam.